Review Article
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
Table 4
CV safety of celecoxib, etoricoxib, and diclofenac in patients with OA and RA.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Myocardial infarction, stroke, and vascular death. Nonfatal myocardial infarction, nonfatal stroke, and vascular death. Per 100 patient-years at risk, per-protocol comparison. Myocardial infarction, stroke, and vascular death. Including cardiac, cerebrovascular, and peripheral vascular events. p < 0.0033. OA, osteoarthritis; RA, rheumatoid arthritis; APTC, Antiplatelet Trialists’ Collaboration; RR, relative ratio; RRR, pooled ratio of relative risks; CV, cardiovascular. |